How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Structural Heart Disease VT

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Optimised DeEP-guided ablation (procedure)
How long the study runs: Study runs about 32 months (dates as stated)
About the drug or intervention: Optimised DeEP-guided ablation — procedure: Optimised decrement evoked potential (DeEP) mapping in VT ablation.
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 77
Started: 2025-04-11
Last checked: 2026-04

Plain English Summary

What is this study?

• Testing a new treatment for structural heart disease
• NA - 77 participants
• Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder

Who can take part?

• Ages 18 Years and over
• Diagnosed with structural heart disease

Where?

• Coventry - University Hospitals Coventry & Warwickshire NHS Trust

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder. Special pacemakers called implantable cardiac defibrillators (ICDs) help treat VT episodes, however they do not prevent the VT episodes from occurring. Catheter ablation for VT is a minimally-invasive and established procedure for preventing VT recurrence. This involves placing wires in the heart to find the diseased areas that are responsible for the VT episodes. The diseased areas are shown on computer-generated maps and are later removed via controlled tissue heating (ablation). A major challenge during the VT ablation procedure is locating the diseased area responsible for the VT episodes. Several methods have been described to locate the diseased heart area, however these methods are not always effective. In this study, we aim to improve the identification of the diseased heart areas responsible for the VT episodes using a novel method. Our research group have developed, tested and peer-reviewed this improved method of locating diseased areas by looking for signals called decrementing evoked potentials (DeEPs). Ablation will target DeEPs shown on the computer-generated maps. We will assess if VT can be triggered at the end of the procedure. Patients will be monitored over 12 months to see if ablation of DeEPs leads to a reduction in VT episodes. We aim to recruit 77 patients with established heart disease of any cause, who have suffered VT episodes with ICDs. Suitable patients will be identified and recruited from inpatient and outpatient settings. A quality-of-life questionnaire will be completed by patients before and after the ablation procedure. The procedure will be performed as routine standard of care, in the cardiac catheter laboratory across multiple recruiting cardiac centres in the UK providing well established VT ablation service. Overall, this study will contribute towards developing refined VT ablation techniques, aiming to improve patient outcomes.

Structural Heart Disease

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

What the study is looking for

✓≥18 years old
✓Patients with heart implantable electronic devices (CIED) (e.g. pacemakers, heart resynchronisation therapy...
✓Eligible for VT ablation as part of standard care (urgent or elective)
✓Catheter ablation of VT ablation using Abbott intracardiac mapping catheter and Ensite intracardiac mapping system.

Who cannot take part

✗Lacks capacity to provide agreement to take part
✗New York Heart Association (NYHA) class IV heart failure
✗Life expectancy of less than 12 months
✗Implanted with a ventricular assist device
✗Presence of mobile intracardiac thrombus

See the full criteria

Inclusion Criteria: * ≥18 years old * Patients with cardiac implantable electronic devices (CIED) (e.g. pacemakers, cardiac resynchronisation therapy (CRT) devices, implantable cardioverter defibrillator (ICD) devices) * Eligible for VT ablation as part of standard care (urgent or elective) * Ischaemic heart disease and prior myocardial infarction (MI) (using the international definition of MI: Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause with documentation of prior ischaemic injury) OR other structural heart disease (such as: arrhythmogenic cardiomyopathy (ACM), or dilated cardiomyopathy (DCM), or hypertrophic cardiomyopathy (HCM), or sarcoidosis, or myocarditis). * Catheter ablation of VT ablation using Abbott intracardiac mapping catheter and Ensite intracardiac mapping system. Exclusion Criteria: * Lacks capacity to provide informed consent * New York Heart Association (NYHA) class IV heart failure * Life expectancy of less than 12 months * Implanted with a ventricular assist device * Presence of mobile intracardiac thrombus * Reversible cause of VT * Women who are pregnant or nursing * Both mechanical aortic and mitral valves * Enrolment in a concurrent interventional clinical study that in the judgement of the investigator would increase risk to the patient or deem the patient inappropriate to participate in this study.

Where Is This Study? (1 UK site)

University Hospitals Coventry & Warwickshire NHS Trust

Coventry CV2 2DX, United Kingdom

Recruiting

Hospital R&D contact (matched)

Josie Goodby

research@uhcw.nhs.uk 02476 965244

How to Get in Touch

Shivam Joshi

Sponsor contact

CONTACT

+442476966907 optodeepstudyoffice@uhcw.nhs.uk

Data sourced from ClinicalTrials.gov · Last verified: 2026-04